Pierre Geborek
1 – 10 of 135
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis
(
- Contribution to journal › Article
- 2017
-
Mark
Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis : Does early anti-TNF therapy bring patients back to work?
(
- Contribution to journal › Article
-
Mark
Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy
(
- Contribution to journal › Article
-
Mark
Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
(
- Contribution to journal › Article
-
Mark
Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine
(
- Contribution to journal › Article
-
Mark
EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy : A prospective observational study of patients registered in the south Swedish SSATG registry
(
- Contribution to journal › Article
-
Mark
Rituximab in clinical practice : dosage, drug adherence, Ig levels, infections, and drug antibodies
(
- Contribution to journal › Article
- 2016
-
Mark
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.
(
- Contribution to journal › Article